GOSS - Gossamer Bio, Inc.
收市後：
| 前收市價 | 1.2600 |
| 開市 | 1.2600 |
| 買盤 | 0.0000 x 4000 |
| 賣出價 | 0.0000 x 2200 |
| 今日波幅 | 1.2200 - 1.3750 |
| 52 週波幅 | 0.9100 - 15.1950 |
| 成交量 | |
| 平均成交量 | 3,087,388 |
| 市值 | 127.895M |
| Beta 值 (5 年，每月) | 1.20 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.3800 |
| 業績公佈日 | 2023年8月07日 - 2023年8月11日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 6.45 |
BenzingaAnalyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ: GOSS) to Market Perform from Outperform following the publication of sotatercept's Phase 3 data in NEJM. The analyst has already thought that seralutinib would exhibit weaker efficacy than Merck & Co Inc's (NYSE: MRK) sotatercept in comparable populations. Using Hodges-Lehman location shift (HLLS) statistic for 6MWD, Merck reported a difference of 40.8m in Phase 3 compared to LSMD of 24.9m in Phase 2, which makes the development path for ser
Insider Monkey15 Most Shorted Stocks Right Now on Wall Street
In this article, we will look at the 15 most shorted stocks on Wall Street right now. If you want to explore similar stocks, you can also take a look at 5 Most Shorted Stocks Right Now on Wall Street. Short selling is a way for traders to make money by betting that the price […]
InvestorPlace7 Top Short-Squeeze Candidates to Watch in February
While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position. At some point, though, those borrowed shares must be returned. For the bears, they can be returned either at a profit or a loss. Now, in order to panic the bears into buying back their borrowed shares befor
BenzingaAnalyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu
BenzingaGossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation
Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study. An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib ar
BenzingaAnalyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial
Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ: GOSS) with a price target down from $18 to $15. The analyst expects a somewhat smaller effect size for seralutinib vs. sotatercept's. Seralutinib Phase 2 TORREY study is on track for topline readout in the second half of November or the first half of December. Merck & Co Inc (NYSE: MRK) is developing sotatercept as an add-on to stable background therapy for pulmonary arterial hypertension (PAH). Merck recently reported topline data